News for RenovoRx, Inc. (RNXT)

RenovoRx, identified by the ticker RNXT, has unveiled plans to scale up the production of its FDA-cleared RenovoCath device. This move comes in response to grow

\n[url=\

\n Projected Q1 2025 revenue in the low six-figure range with expected sequential growth. Estimated total addressable market of $400 million in peak an

[url="]RenovoRx, Inc.[/url] (”œRenovoRx” or the ”œCompany”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and

[url="]RenovoRx, Inc[/url]. (”œRenovoRx” or the ”œCompany”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and

[url="]RenovoRx, Inc.[/url] (”œRenovoRx” or the ”œCompany”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and

[url="]RenovoRx, Inc[/url]. (”œRenovoRx” or the ”œCompany”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and

[url="]RenovoRx, Inc[/url]. (”œRenovoRx” or the ”œCompany”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and comm

California-based Conduit Pharmaceuticals Inc. (CDT), a clinical-stage specialty biopharmaceutical company is up over 79 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

RenovoRx (RNXT, Financials) announced the pricing of an underwritten public offering, aiming to raise approximately $12.1 million through the sale of 11,523,810

RenovoRx, Inc. (”œRenovoRx” or the ”œCompany”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing R

RenovoRx, Inc. (”œRenovoRx” or the ”œCompany”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing R

RenovoRx's innovative RenovoCath and TAMP platform show promising clinical data. Click here to read why RNXT stock presents an asymmetric opportunity.

[url="]RenovoRx, Inc.[/url] (”œRenovoRx” or the ”œCompany”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and comm

RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer

TIGeR-PaC is Evaluating the TAMPâ„¢ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer Dr. Meredith Pels

RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET

Over Ten Medical Institutions Nationwide have Initiated RenovoCath Purchase Process, Further Accelerating Commercialization Strategy RenovoRx Estimates Initial

Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program.